CSL312 (garadacimab) in the prevention of hereditary angioedema attacks
Phase 3
Completed
- Conditions
- Hereditary angioedema
- Registration Number
- JPRN-jRCT2031210056
- Lead Sponsor
- Akama Hideto
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Male or female >= 12 years of age; diagnosed with clinically confirmed C1-INH hereditary angioedema; experience >= 3 attacks during the 3 months before screening
Exclusion Criteria
Concomitant diagnosis of another form of angioedema such as idiopathic or acquired angioedema, recurrent angioedema associated with urticarial or hereditary angioedema type 3
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method